STOCK TITAN

Eton Pharmaceuticals (ETON) awards director 10,000 performance RSUs

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Adams Jennifer McKie reported acquisition or exercise transactions in this Form 4 filing.

Eton Pharmaceuticals director Jennifer McKie Adams received a grant of 10,000 performance‑vested restricted stock units under the 2018 equity incentive plan. Each unit represents one share, vesting only if the stock closes at $72.36 or higher for one trading day before July 31, 2029; otherwise the award is forfeited.

Positive

  • None.

Negative

  • None.
Insider Adams Jennifer McKie
Role Director
Type Security Shares Price Value
Grant/Award Common Stock F1 10,000 $0.00 $0.00
Holdings After Transaction: Common Stock — 10,000 shares (Direct)
Footnotes (1)
  1. F1. On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range.
RSU Grant Size 10,000 units Performance-vested restricted stock units granted July 31, 2026
Vesting Price Condition $72.36 per share Stock closing price required for one trading day for award to vest
Forfeiture Date July 31, 2029 Award forfeited without consideration if price condition not met by this date
performance-vested restricted stock units financial
"was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018"
equity incentive plan financial
"was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan."
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
market condition financial
"If this market condition is not satisfied prior to such date, the award"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did ETON director Jennifer McKie Adams receive in this Form 4 filing?

Jennifer McKie Adams received 10,000 performance‑vested restricted stock units from Eton Pharmaceuticals. Each RSU represents the right to acquire one share of common stock, subject to a stock‑price performance condition and potential forfeiture if that condition is not met.

What performance condition applies to Jennifer McKie Adams’s 10,000 ETON RSUs?

The RSUs vest only if Eton’s stock closing price reaches or exceeds $72.36 per share for one trading day. This market condition must occur at any time before the third anniversary of the July 31, 2026 grant date.

When do Jennifer McKie Adams’s ETON RSUs expire if the condition is not satisfied?

If the $72.36 stock‑price condition is not met, the RSU award is forfeited in its entirety on July 31, 2029. No shares will be issued and no consideration will be paid if forfeiture occurs.

How many ETON shares can be issued under Jennifer McKie Adams’s RSU award?

The award can result in a maximum of 10,000 shares of Eton Pharmaceuticals common stock. The filing states this is the maximum and only number of shares issuable, with no target, threshold, or range for the grant.

Was Jennifer McKie Adams’s ETON Form 4 transaction under a Rule 10b5-1 trading plan?

The Form 4 indicates the Rule 10b5‑1 checkbox is not marked, and there is no footnote describing a pre‑arranged trading plan. The reported grant therefore is not characterized as made under a Rule 10b5‑1 plan.

What plan governs the 10,000 RSU grant to ETON director Jennifer McKie Adams?

The 10,000 performance‑vested RSUs were granted under Eton Pharmaceuticals’ 2018 equity incentive plan. This plan provides the framework for equity‑based awards such as restricted stock units to directors and other eligible participants.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Adams Jennifer McKie

(Last)(First)(Middle)
C/O ETON PHARMACEUTICALS, INC.
21925 W. FIELD PARKWAY, SUITE 235

(Street)
DEERPARK ILLINOIS 60010-7208

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Eton Pharmaceuticals, Inc. [ ETON ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Common Stock(1)07/31/2026A10,000 (1) (1)Common Stock10,000$010,000D
Explanation of Responses:
1. On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range.
Remarks:
The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.
/s/ Judith Matthews08/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)